Lu Lu, Li Yuan, Su Hang, Ren Sisi, Liu Yujing, Shao Gaoxuan, Liu Weiwei, Ji Guang, Xu Hanchen
Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases (ccCRDD), Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
J Pharm Anal. 2025 May;15(5):101138. doi: 10.1016/j.jpha.2024.101138. Epub 2024 Nov 4.
Colorectal inflammatory cancer transformation poses a major risk to patients with colitis. Patients with chronic intestinal inflammation have an approximately 2-3 folds increased risk of developing colorectal cancer (CRC). Unfortunately, there is currently no effective intervention available. Huangqin decoction (HQD), a well-known traditional Chinese medicine (TCM) formula, is frequently clinically prescribed for treating patients with colitis, and its active ingredients have effective antitumour efficacy. Nonetheless, the mechanism of HQD-mediated prevention of colorectal inflammatory cancer transformation remains unclear. A strategy integrating metagenomic, lipidomic, and messenger RNA (mRNA) sequencing analysis was used to investigate the regulatory effects of HQD on the gut microbiome, metabolism and potential mechanisms involved in colorectal inflammatory cancer transformation. Our study revealed that HQD suppressed colorectal inflammatory cancer transformation, which was associated with enhanced intestinal barrier function, decreased the inflammatory response, and regulation of the gut microbiome. Notably, cohousing experiments revealed that the transfer of the gut microbiome from HQD-treated mice largely inhibited the pathological transformation of colitis. Moreover, gut microbiome transfer from HQD-treated mice primarily resulted in the altered regulation of fatty acid metabolism, especially the remodeling of arachidonic acid metabolism, which was associated with the amelioration of pathological transformation. Arachidonic acid metabolism and the key metabolic enzyme arachidonic acid 12-lipoxygenase (ALOX12) were affected by HQD treatment, and no obvious protective effect of HQD was observed in mice, which revealed that ALOX12 was a critical mediator of HQD protection against colorectal inflammatory cancer transformation. In summary, multiple omics analyses were applied to produce valuable data and theoretical support for the application of HQD as a promising intervention for the transformation of inflammatory CRC.
结直肠炎性癌转化对结肠炎患者构成重大风险。患有慢性肠道炎症的患者患结直肠癌(CRC)的风险增加约2至3倍。不幸的是,目前尚无有效的干预措施。黄芩汤(HQD)是一种著名的中药配方,临床上常用于治疗结肠炎患者,其活性成分具有有效的抗肿瘤功效。尽管如此,HQD介导预防结直肠炎性癌转化的机制仍不清楚。本研究采用宏基因组学、脂质组学和信使核糖核酸(mRNA)测序分析相结合的策略,研究HQD对肠道微生物群、代谢的调节作用以及结直肠炎性癌转化的潜在机制。我们的研究表明,HQD抑制了结直肠炎性癌转化,这与增强肠道屏障功能、减轻炎症反应以及调节肠道微生物群有关。值得注意的是,同笼实验表明,将经HQD处理小鼠的肠道微生物群进行移植,在很大程度上抑制了结肠炎的病理转化。此外,将经HQD处理小鼠的肠道微生物群进行移植,主要导致脂肪酸代谢调节的改变,尤其是花生四烯酸代谢的重塑,这与病理转化的改善有关。花生四烯酸代谢和关键代谢酶花生四烯酸12-脂氧合酶(ALOX12)受HQD处理的影响,在ALOX12基因敲除小鼠中未观察到HQD的明显保护作用,这表明ALOX12是HQD预防结直肠炎性癌转化的关键介质。总之,本研究应用多种组学分析方法,为HQD作为一种有前景的干预措施用于炎性结直肠癌转化的应用提供了有价值的数据和理论支持。